Dr. Robert Michael Barone, MD

Dr. Barone practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Barone's NPI, 1528083573, was assigned on July 12, 2006. Dr. Barone graduated from Jacobs School of Medicine and Biomedical Sciences in 1966. Dr. Barone holds California license G22669.

Dr. Barone's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Barone's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Barone is also affiliated with Hillcrest Medical Center. The medical group on file is Emergency and Acute Care Medical Corporation. Dmand AI also links Dr. Barone to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Barone practices, 2 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Barone's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Barone is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Barone's licenses on file in 2 states: California and Illinois.

Dmand AI lists mastectomy among the conditions Dr. Barone treats.

CMS data shows 86 Medicare services from Dr. Barone across 1 procedure code in 2024, all of them office visits, for 93 Medicare patients. Medicare paid $4,345 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 93 Medicare patients who saw Dr. Barone in 2024. The largest group is 75 to 84, with 39 patients. 74% of them have high cholesterol, and 67% have cancer. Their average risk score is 1.34, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Barone's median patient age at 70, with 71% women.

In 2024, Dr. Barone wrote 19 Medicare Part D claims for 14 patients. 100% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $106 in total drug cost. In 2017, CMS named 33 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Barone for performance year 2024, reported as part of a group.

Dmand AI links 9 papers to Dr. Barone, published from 2013 to 2020. 2019 was the busiest year, with 2. The most frequent topics are Magnetic Resonance Imaging, Peritoneal Neoplasms and Appendiceal Neoplasms. Dr. Barone has published most often in Ann Surg Oncol. Dr. Barone's most frequent co-authors are Jula Veerapong, MD, Doreen M. Agnese, MD and Charlotte Eielson Ariyan, MD, PhD.

Dmand AI links Dr. Barone to 4 clinical trials, 2 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Carcinoma, Intraductal, Noninfiltrating, COVID-19 and Pancreatic Intraductal Neoplasms. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 20 general payments to Dr. Barone from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 83% of the total. Integra LifeSciences Corporation paid the most, $366.

Dr. Barone graduated from Jacobs School of Medicine and Biomedical Sciences in 1966.

Dr. Barone is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.